Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP8 | P22894 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174555 | 0.77 | CYP3A4 (0.49) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL11570838 | 0.74 | CYP3A4 (0.47) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL15972776 | 0.74 | ALDH1A1 (0.60) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL7097777 | 0.74 | ALDH1A1 (0.60) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL5448618 | 0.74 | MMP9 (0.64) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL5180824 | 0.73 | ADAM17 (0.79) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL4852554 | 0.71 | CYP3A4 (0.44) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL9402123 | 0.70 | CYP3A4 (0.43) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL16865403 | 0.69 | MMP9 (0.50) | MMP9MMP2MMP8MMP13CYP3A4 | |
| SCHEMBL7475063 | 0.69 | MMP9 (0.50) | MMP9MMP2MMP8MMP13CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0918059-B1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-06-25 | — | — | EP | disclosed |
| US-6521654-B2 | For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| EP-0918059-A1 | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | MMP9 395/4885MMP2 493/4885MMP8 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.